How can emerging disease-modifying therapies reshape the trajectory of type 1 diabetes?

In this episode, our host, Dr. Alice Cheng, discusses the cutting-edge landscape of type 1 diabetes (T1D) prevention and intervention with Dr. Bruce Perkins, endocrinologist, epidemiologist, clinician-scientist, and professor in the Faculty of Medicine and the Institute for Health Policy, Management and Evaluation at the University of Toronto.

Join our experts as they explore how T1D care is shifting from symptom management through insulin replacement toward early intervention in a disease that develops silently over years. Discover the clinical benefits of early disease modification and the transformative potential of novel therapeutic targets in delaying T1D onset and preserving beta-cell function. Learn about the practical mechanics of emerging therapies, where they precisely target the immune system, and how clinicians can take practical steps to screen, identify, and intervene before clinical symptoms or hyperglycemia present.

Tune in as we discuss the future of T1D care, exploring how population-wide screening and precision biomarker matching are actively bridging the critical gap between groundbreaking research and its clinical application.

Don't miss this discussion!

The opinions and views expressed in this episode are those of the speakers and do not necessarily reflect the position of the entities they represent.

Declaration of conflict of interest:

Dr. Alice Cheng:

Direct financial links, including receipt of fees: Abbott, Amgen, Aspen, Astellas, AstraZeneca, Bausch, Bayer, Biomea, Boehringer Ingelheim, Caliway Biopharmaceutics, Dexcom, Eisai, Eli Lilly, Gan & Lee, Insulet, HLS Therapeutics, Medtronic, Merck, MSD, Novo Nordisk, Sandoz, Sanofi, Vertex, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MDBriefCase, LMC Physician Inc., Medscape, Humber River Health, TimedRight, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, American Diabetes Association, The Rounds, PeerVoice, Virtual Hallway, Diversified Canada. Advisory Committee or Speaker Bureau Members: Abbott, Amgen, Aspen, Astellas, AstraZeneca, Bausch, Bayer, Biomea, Boehringer Ingelheim, Caliway Biopharmaceuticals, Dexcom, Eisai, Eli Lilly, Gan & Lee, Insulet, HLS Therapeutics, Medtronic, Merck, MSD, Novo Nordisk, Sandoz, Sanofi, Vertex. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

Dr. Bruce Perkins:

Direct financial links, including receipt of fees: Abbott, Dexcom, Insulet NovoNordisk, Sanofi. Advisory Committee or Speaker Bureau Members: Abbott, Dexcom, Insulet, Nephris NovoNordisk, Sanofi, Vertex. Funded grants, research, or clinical trials: NIH-NIDDK, Diabetes Canada.

MAT-CA-2601068

Managing hypoglycemia remains a persistent, high-stakes challenge for both clinicians and the patients they support. What are the updates to the Diabetes Canada Clinical Practice Guidelines for Hypoglycemia and how can these be integrated into daily practice immediately?

Our host, Dr. Jeremy Gilbert, an Endocrinologist at Sunnybrook Health Sciences Centre and Associate Professor at the University of Toronto, discusses standardizing hypoglycemia safety with Dr. Akshay Jain, a Clinical Endocrinologist and Medical Director for Research at Unity Healthcare based in Surrey, British Columbia.

Together, our experts explore the complex clinical realities and systemic gaps surrounding hypoglycemia management. They discuss the practical implications of the updated Diabetes Canada guidelines, detailing the new three-level classification of hypoglycemia, and the symptoms associated with each level. They highlight the importance of prevention, strategies for monitoring, and important conversations to have with patients about hypoglycemia. Tune in to hear practical, actionable tips for managing hypoglycemia to better support individuals living with diabetes.

Don’t miss the conversation! 

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent. 

Declaration of conflict of interest:  

Dr. Jeremy Gilbert:

• Direct financial relationship, including receipt of honoraria: CPD Network, LMC Canada Inc., CSEM, S+L Solutions, Liv Agency, Unik Agency, STA. Membership on advisory boards or speaker’s bureaus: Abbott, Amgen, Bayer, Insulet, Tandem, Boehringer Ingelheim, Eli Lilly, GSK, HLS Therapeutics, Novartis, Novo Nordisk.

Dr. Akshay Jain:

• Direct financial relationship, including receipt of honoraria: Abbott, Abbvie, AstraZeneca, Amgen, Antibody, Bausch Healthcare, Bayer, Boehringer Ingelheim, Care to Know, CCRN, Connected in Motion, CPD Network, Dexcom, Diabetes Canada, Eli Lilly, Embecta, EOCI, GSK, HLS Therapeutics, Janssen, Liv, Master Clinician Alliance, MDBriefcase, Merck, Medtronic, Moderna, NP Circle, Novartis, Novo Nordisk, Partners in Progressive Medical Education, Pfizer, Roche, Six Degrees, Timed Right, Unik, WebMD. Membership on advisory boards or speaker’s bureaus: Abbott, AstraZeneca, Amgen, Bausch Healthcare, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Embecta, Gilead Sciences, GSK, HLS Therapeutics, Industrii, Insulet, Janssen, Medtronic, NP Circle, Novartis, Novo Nordisk, Partners in Progressive Medical Education, Pendopharm, PocketPills, Roche, Sandoz, Takeda, Ypsomed. Funded grants, research, or clinical trials: Abbott, Amgen, Argenx, Astra Zeneca, Novo Nordisk, Roche, Sanofi.

MAT-CA-2600837

What is the role of early detection of type 1 diabetes and how can it be integrated into clinical practice?

In this episode, our host, Dr. Maha Lebbar, discusses the practical aspects of screening for type 1 diabetes (T1D) with Dr. Rémi Rabasa-Lhoret, endocrinologist at Centre Hospitalier de L’Université de Montréal (CHUM), professor and researcher at the Montréal Clinical Research Institute (IRCM).

Join our experts as they discuss the clinical benefits of early T1D identification and the transformative potential of early interventions in improving long-term health outcomes and preventing severe complications. Learn about the practical steps and options for T1D screening, gaining in-depth insights into various screening pathways, existing programs, and promising research initiatives driving innovation in this field. Tune in as we explore how studies such as FEDERATE Can are actively bridging the critical gap between research and its practical application in clinical settings.

Discover concrete recommendations for healthcare providers to integrate early detection of T1D into their everyday practice, including workflow considerations for screening, monitoring, and follow-up.

Don't miss this discussion!

The opinions and views expressed in this episode are those of the speakers and do not necessarily reflect the position of the entities they represent.

Declaration of conflict of interest:

Dr Maha Lebbar:

• Direct financial links, including receipt of fees: Sanofi. Receipt of grants or funding for research projects or clinical trials: Sanofi.

Dr Rémi Rabasa-Lhoret:

• Direct financial links, including receipt of fees: Abbott, CPD Network, Dexcom, Eli Lilly, Janssen, Medtronic, Merck, Novo Nordisk, Sanofi, Tandem Diabetes Care, Vertex Pharmaceuticals. Advisory Committee or Speaker Bureau Members: 35Pharma Inc., Abbott, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GlaxoSmithKline Inc., HLS Therapeutics, INESSS, Insulet, Medtronic, Merck, Novo Nordisk, Sanofi, Ypsomed. Receipt of grants or funding for research projects or clinical trials: Diabetes Canada, Cystic Fibrosis Canada, Canadian Institutes of Health Research (CIHR), Diabetes Research Foundation (JDRF), Novo Nordisk, Société francophone du diabetes, Medtronic, Merck, Sanofi. Patents relating to a medicine, product or medical device: Eli Lilly.

MAT-CA-2200968

How can T1D screening programs be effectively established in the clinic, and what are the considerations to get started?

Our host, Dr. Alice Cheng, explores this topic with James Stainer, a Registered Nurse and Certified Diabetes Educator at Windsor-Essex Community Health Centre.

Join our experts for a foundational discussion detailing the initiation of the first community-based T1D screening program in Canada at Windsor-Essex Community Health Care Centre. Learn about important considerations throughout the planning and screening process including strategies to garner awareness, share results, and facilitate continued monitoring. Hear about how the multidisciplinary screening team collaborates and is setting the stage for additional programs towards the proactive detection of T1D.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Alice Cheng:

· Direct financial relationship, including receipt of honoraria: Abbott, Amgen, Astellas, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, Vertex, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MD Briefcase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, ADA. Membership on advisory boards or speaker’s bureaus: Abbott, Amgen, Astellas, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, Vertex. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

James Stainer:

· Direct financial relationship, including receipt of honoraria: Sanofi, Dexcom, Abbott, Eli Lilly, Novo Nordisk, Janssen. Membership on advisory boards or speaker’s bureaus: Sanofi, Abbott, Eli Lilly. Funded grants, research, or clinical trials: AstraZeneca.

MAT-CA-2600205

How can healthcare providers best navigate the unique complexities of diabetes in an aging population?

Our host, Dr. Jeremy Gilbert, explores the multifaceted nature of type 2 diabetes management in the elderly with Dr. Peter Lin, Director of Primary Care Initiatives at the Canadian Heart Research Centre and contributing author to the Diabetes Canada Clinical Practice Guidelines.

In this episode, our experts delve into crucial considerations for managing diabetes in older people, including comorbidities, cognition, frailty, hypoglycemia risk, and the use of basal insulins. Hear our experts share their practical strategies for prioritizing care goals, personalizing treatment approaches, fostering multidisciplinary teamwork, and ensuring patient safety and well-being in this vulnerable population.

Don’t miss the conversation! 

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent. 

Declaration of conflict of interest:  

Dr. Jeremy Gilbert:

• Direct financial relationship, including receipt of honoraria: CPD Network, LMC Canada Inc., CSEM, S&L Solutions, liV Agency, Unik Agency, STA. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Abbott, Amgen, Bayer, Insulet, Tandem, Boehringer Ingelheim, Eli Lilly, GSK, HLS Therapeutics, Novartis, Novo Nordisk, Sanofi.

Dr. Peter Lin:

• Direct financial relationship, including receipt of honoraria: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes & Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes & Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape.

MAT-CA-2500991

How can early identification transform type 1 diabetes (T1D) care and what groundbreaking advances are on the horizon?

Our host, Dr. Alice Cheng, explores this topic with Dr. Karen McAssey, a pediatric endocrinologist, researcher, educator, and advocate for people living with T1D at McMaster Children's Hospital in Hamilton, Ontario.

Join our experts for a compelling conversation that delves into the profound impact of diabetic ketoacidosis (DKA) and unveils how early intervention can change the course of T1D. Discover why preventing DKA at diagnosis is paramount, learn about the latest consensus guidance for monitoring early-stage T1D, and hear about exciting Canadian research developments shaping the future of T1D screening, monitoring, and prevention.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Alice Cheng:

· Direct financial relationship, including receipt of honoraria: Abbott, Amgen, Astellas, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, Vertex, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MD Briefcase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, ADA. Membership on advisory boards or speaker’s bureaus: Abbott, Amgen, Astellas, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, MSD, Novo Nordisk, Pfizer, Sandoz, Sanofi, Vertex. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

Dr. Karen McAssey:

· Direct financial relationship, including receipt of honoraria: Dexcom, Medtronic, Tandem. Membership on advisory boards or speaker’s bureaus: Abbott, Dexcom, Insulet, Eli Lilly, Medtronic, Sanofi. Funded grants, research, or clinical trials: DRF, NIH-NIDDK, Medtronic.

MAT-CA-2500921

What are the most effective ways for a diabetes care team to tackle the complexities and challenges of insulin management for patients?

Our host, Dr. Alice Cheng, discusses practical approaches in coordinating multidisciplinary diabetes care with Dr. Michelle Long, a Primary Care Physician based in Port Hope, Ontario, with more than 30 years in clinical practice, and Ms. Susie Jin, a Pharmacist and Certified Diabetes Educator based in Cobourg, Ontario, recognized for her national leadership in diabetes.

Together, our experts explore the importance of a connected care team—including endocrinologists, general practitioners, pharmacists, and diabetes educators—in optimizing insulin use for patients with diabetes. They discuss strategies for initiating insulin conversations, dispelling misconceptions, and leveraging the expertise of the entire care team. Tune in to hear practical tips for improving communication and collaboration among healthcare providers to better support individuals living with diabetes, especially in resource-limited settings.

Don’t miss the conversation! 

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent. 

Additional resource for healthcare providers:

‘Insulin Pen Start Checklist’

Available at: https://guidelines.diabetes.ca/reduce-complications/insulin-checklist

Declaration of conflict of interest:  

Dr. Alice Cheng:

• Direct financial relationship, including receipt of honoraria: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MD Briefcase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, ADA. Membership on advisory boards or speaker’s bureaus: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

Dr. Michelle Long:

• None.

Ms. Susie Jin:

• Direct financial relationship, including receipt of honoraria: Abbott, AbbVie, Boehringer Ingelheim, Dexcom, Sol-M, Canadian Association of Pharmacy Technicians, Canadian Pharmacists Association, Diabetes Canada, Manitoba Pharmacists Association, Ontario Pharmacists Association, Sun Life, Wounds Canada. Membership on advisory boards or speaker’s bureaus: AbbVie, Dexcom, Kenvue, Eli Lilly. Funded grants, research, or clinical trials: Boehringer Ingelheim.

MAT-CA-2500670

Curious about how primary care practitioners are managing the complexities of type 2 diabetes (T2D) in their practice?

Join our host Dr. Alice Cheng as she delves into this topic with Dr. James Kim, Clinical Assistant Professor in the Department of Family Medicine at the University of Calgary, lead editor for the Primary Care section of the Canadian Journal of Diabetes, and a key contributor within Diabetes Canada.

Our experts examine the critical role that primary care plays in the early diagnosis of T2D, personalizing and implementing treatment plans, and facilitating regular screening for potential complications. They stress the importance of managing both the physical and mental health of people living with diabetes, and provide practical strategies for organizing care and for maximizing the use of community resources.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Alice Cheng:

• Direct financial relationships, including receipt of honoraria: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MDBriefCase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, American Diabetes Association. Membership on advisory boards or speakers’ bureaus: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

Dr. James Kim:

• Direct financial relationships, including receipt of honoraria: Abbott, AbbVie, AstraZeneca, Boehringer Ingelheim, Eisai, embecta, Eli Lilly, GSK, Janssen, Novo Nordisk, Pfizer, Sanofi, Takeda, Searchlight, Otsuka, Teva. Membership of advisory board or speakers’ bureaus: Abbott, AbbVie, ALK, AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, embecta, Eli Lilly, GSK, Novo Nordisk, Sanofi, Teva, Takeda, Searchlight, Valeo. Funded grants, research, or clinical trials: Novo Nordisk. All other investments or relationships: MDBriefCase, CPD Network, Academy for Continued Advancement in Healthcare Education, EOCI, Family Physician Airway Group of Canada, Liv Agency, PPME, CCRN.

MAT-CA-2401556

How is our understanding of autoimmunity in type 1 diabetes (T1D) shifting the way it’s detected and treated?

Our host, Dr. Alice Cheng, discusses this topic and more with Dr. Bruce Perkins, Professor, Endocrinologist, Epidemiologist, and Clinician-Scientist in the Faculty of Medicine and the Institute for Health Policy Management and Evaluation at the University of Toronto.

In this episode, the stages of T1D development and the role of autoimmunity are summarized, before examining the clinical benefits and challenges of autoantibody testing for the early detection of T1D. Current practices are discussed, as well as who should be prioritized for screening. Finally, our experts explore future directions of population-wide screening initiatives with the hopes of delaying or preventing clinical onset in those at high risk of developing T1D.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Alice Cheng:

• Direct financial relationship, including receipt of honoraria: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MD Briefcase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, ADA. Membership on advisory boards or speakers’ bureaus: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

Dr. Bruce Perkins:

• Direct financial relationship, including receipt of honoraria or in-kind compensation: Abbott, Sanofi, Insulet, Medtronic, Novo Nordisk. Membership on advisory boards or speakers’ bureaus: Abbott, Insulet, Sanofi, Novo Nordisk, Vertex. Funded grants, research, or clinical trials: Novo Nordisk, Bank of Montreal. Patents on a drug, product, or device: Boehringer Ingelheim.

MAT-CA-2401456 Nov 2024

What do we know about the developmental stages of type 1 diabetes (T1D), and how can this understanding ultimately lead to improved patient outcomes?

Our host, Dr. Alice Cheng, explores these questions with Dr. Bruce Perkins, Professor, Endocrinologist, Epidemiologist, and Clinician-Scientist in the Faculty of Medicine and the Institute for Health Policy Management and Evaluation at the University of Toronto.

Our experts kick off the discussion by identifying the key differentiators between type 1 and type 2 diabetes, before diving into the presence and involvement of autoantibodies in the development of T1D. Dr. Perkins details the stages of T1D, and explains how identification of early stages has the potential to improve patient outcomes and prevent serious illness.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Alice Cheng:

• Direct financial relationship, including receipt of honoraria: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MD Briefcase, LMC Physician Inc., Medscape, Humber River Health, Timed Right, The ACADEMY, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, ADA. Membership on advisory boards or speakers’ bureaus: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, Insulet, HLS Therapeutics, Medtronic, Novo Nordisk, Pfizer, Sanofi. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi.

Dr. Bruce Perkins:

• Direct financial relationship, including receipt of honoraria or in-kind compensation: Abbott, Sanofi, Insulet, Medtronic, Novo Nordisk. Membership on advisory boards or speaker’s bureaus: Abbott, Insulet, Sanofi, Novo Nordisk, Vertex. Funded grants, research, or clinical trials: Novo Nordisk, Bank of Montreal. Patents on a drug, product, or device: Boehringer Ingelheim.

MAT-CA-2401455 Nov 2024